AstraZeneca presents new data on Tagrisso ▼ (osimertinib) for EGFR-mutated non-small cell lung cancer

Man sat at desk to show AstraZeneca presents new data on Tagrisso

AstraZeneca has presented new data on Tagrisso (osimertinib) for EGFR-mutated non-small cell lung cancer. They are detailed overall survival (OS) results from the Phase III FLAURA trial of Tagrisso (osimertinib) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer.

Results showed a statistically significant and clinically meaningful improvement in OS, a key secondary endpoint for osimertinib versus gefitinib or erlotinib, both of which were previous standard-of-care treatments in this setting (HR 0.799 [95% CI, 0.641-0.997], p=0.0462).

Osimertinib delivered a median OS of 38.6 months versus 31.8 months for the comparator arm. At three years, 28% of patients in the osimertinib arm and 9% of patients in the comparator arm remained on 1st-line study treatment. Osimertinib also showed a statistically significant and clinically meaningful 52% reduction in the risk of central nervous system disease progression, increasing the time patients with CNS metastases lived without CNS disease progression or death (HR 0.48 [95% CI, 0.26-0.86], p=0.014).

The new data on Tagrisso were presented at the Presidential Symposium of the ESMO (European Society for Medical Oncology) 2019 Congress in Barcelona, Spain (Abstract #LBA5_PR).

In June, it was announced that AstraZeneca was to appeal a decision by the National Institute for Health and Care Excellence not to recommend Tagrisso (osimertinib) for use within NHS England.